TCL Archive FDA approves a new cancer drug, Vidaza, and two sNDAs, without going to ODAC. A date with ODAC may signal a weak case for drug approval, recent approval data indicate. May 28, 2004
TCL Archive Also Cancer policy board urges NCI to convene panel on long-term care for childhood cancer survivors. October 10, 2003
TCL Archive In Brief: Peter Fischinger Names NCI Deputy Director; ACR Moves Headquarters To Washington Area November 8, 1985
